Cholesteryl ester transfer protein inhibition in the management of atherosclerotic cardiovascular disease: Second act "a rebirth of hope";Inhibición de la proteína de transferencia de ésteres de colesterol para el manejo de la enfermedad cardiovascular ateroesclerótica: El segundo acto "una esperanza que renace"

Revista Medica de Chile

Volumn 139, Issue 6, 2011, Pages 802-806

  Arteaga, Antonio ^a   Rigotti, Attilio ^a,b  

^a Escuela de Medicina   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Cholesterol; Cholesterol ester transfer proteins; HDL; Heart diseases

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; HYPOCHOLESTEROLEMIC AGENT;

ARTERIOSCLEROSIS; ARTICLE; DRUG ANTAGONISM; HUMAN;

ANTICHOLESTEREMIC AGENTS; ARTERIOSCLEROSIS; CHOLESTEROL ESTER TRANSFER PROTEINS; HUMANS;

EID: 81755186899     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: 10.4067/S0034-98872011000600016     Document Type: Article

References (27)

1. Cholesterol treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81.
2. Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A. Growing epidemic of coronary heart disease in low -and middle-income countries. Curr Probl Cardiol 2010; 35: 72-115.
3. Laris R, Arteaga A, Cuevas A, Rigotti A. [HDL cholesterol: a new target in the treatment of lipid disorders and atherosclerosis?] Rev Med Chile 2005; 133: 823-32.
4. Guyton JR. Extended-release niacin for modifying the lipoprotein profile. Expert Opin Pharmacother 2004; 5: 1385-98.
5. Olsson AG. Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease. Expert Opin Pharmacother 2010; 11: 1715-26.
6. http://www.aimhigh-heart.com
7. http://www.ctsu.ox.ac.uk/projects/hps2-thrive
8. Bambs C, Rigotti A. Inhibición de CETP y ateroesclerosis: ¿hay todavía alguna esperanza después del fracaso de torcetrapib? Rev Chil Cardiol 2007; 26: 213-6.
9. Davidson MH. Update on CETP inhibition. J Clin Lipidol. 2010; 4:394-8.
10. When good cholesterol turns bad. Nature 2006; 444: 794-5.
11. The good, the bad, and the stopped trial. Lancet 2006; 368: 2034.
12. Honey K. Drug designed to raise HDL levels falls down. J Clin Invest 2007; 117: 282.
13. Morehouse LA, Sugarman ED, Bourassa PA, Sand TM, Zimetti F, Gao F, et al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J Lipid Res 2007; 48: 1263-72.
14. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004; 350: 1505-15.
15. Nissen S, Tardif JC, Nicholls S, Revkin JH, Shear CL, Duggan WT, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007; 356: 1304-16.
16. Kastelein J, Van Leuven S, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007; 356: 1620-30.
17. Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007; 370: 153-60.
18. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109-22.
19. Forrest MJ, Bloomfield D, Briscoe RJ, Brown PN, Cumiskey AM, Ehrhart J, et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 2008; 154: 1465-73.
20. Hu X, Dietz JD, Xia C, Knight DR, Loging WT, Smith AH, et al. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology 2009; 150: 2211-9.
21. Vergeer M, Stroes ES. The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors. Am J Cardiol 2009; 104: 32E-38E.
22. Krishna R, Anderson MS, Bergman AJ, Jin B, Fallon M, Cote J, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 2007; 370: 1907-14.
23. Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010; 363: 2406-15.
24. http://abcnews.go.com/Health/Cholesterol/goodcholesterol-dramatically-raised-drug-anacetrapib-study/story?id=12164378
25. http://clinicaltrials.gov/ct2/show/NCT01252953
26. Robinson JG. Dalcetrapib: a review of Phase II data. Expert Opin Investig Drugs 2010; 19: 795-805.
27. Steinberg D. The Cholesterol Wars: The Skeptics vs. the Preponderance of the Evidence. Academic Press, New York, 2007.